...
aqst-img

Aquestive Therapeutics Inc, Common Stock

AQST

NMQ

$3.82

+$0

(0%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$348.30M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.50M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.82
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.84 L
$6.23 H
$3.82

About Aquestive Therapeutics Inc, Common Stock

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameAQSTSectorS&P500
1-Week Return-11.37%-1.8%-0.77%
1-Month Return-24.65%-3.48%0.71%
3-Month Return-22.83%-7.2%8.81%
6-Month Return35.94%-1.54%12.32%
1-Year Return93.91%8.39%30.57%
3-Year Return-23.75%6.07%29.21%
5-Year Return-50.39%44.07%91.95%
10-Year Return-76.2%106.3%196.04%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue52.61M45.85M50.83M47.68M50.58M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":87.15,"profit":true},{"date":"2021-12-31","value":96.62,"profit":true},{"date":"2022-12-31","value":90.63,"profit":true},{"date":"2023-12-31","value":96.15,"profit":true}]
Cost of Revenue20.36M12.96M14.99M19.39M20.83M[{"date":"2019-12-31","value":97.74,"profit":true},{"date":"2020-12-31","value":62.23,"profit":true},{"date":"2021-12-31","value":71.96,"profit":true},{"date":"2022-12-31","value":93.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit32.25M32.88M35.84M28.29M29.75M[{"date":"2019-12-31","value":89.97,"profit":true},{"date":"2020-12-31","value":91.75,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":78.94,"profit":true},{"date":"2023-12-31","value":83.01,"profit":true}]
Gross Margin61.30%71.72%70.51%59.34%58.82%[{"date":"2019-12-31","value":85.46,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":98.31,"profit":true},{"date":"2022-12-31","value":82.74,"profit":true},{"date":"2023-12-31","value":82.01,"profit":true}]
Operating Expenses84.92M75.78M70.52M70.36M44.85M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":89.24,"profit":true},{"date":"2021-12-31","value":83.05,"profit":true},{"date":"2022-12-31","value":82.86,"profit":true},{"date":"2023-12-31","value":52.82,"profit":true}]
Operating Income(52.67M)(42.89M)(34.68M)(42.07M)(15.10M)[{"date":"2019-12-31","value":-5266800000,"profit":false},{"date":"2020-12-31","value":-4289300000,"profit":false},{"date":"2021-12-31","value":-3467900000,"profit":false},{"date":"2022-12-31","value":-4206600000,"profit":false},{"date":"2023-12-31","value":-1510200000,"profit":false}]
Total Non-Operating Income/Expense(22.26M)(25.78M)(57.90M)(24.69M)16.34M[{"date":"2019-12-31","value":-136.26,"profit":false},{"date":"2020-12-31","value":-157.81,"profit":false},{"date":"2021-12-31","value":-354.42,"profit":false},{"date":"2022-12-31","value":-151.13,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(66.25M)(55.78M)(70.54M)(54.41M)(7.63M)[{"date":"2019-12-31","value":-6624600000,"profit":false},{"date":"2020-12-31","value":-5578300000,"profit":false},{"date":"2021-12-31","value":-7053900000,"profit":false},{"date":"2022-12-31","value":-5441000000,"profit":false},{"date":"2023-12-31","value":-762500000,"profit":false}]
Income Taxes6.41M9.58M19.50M5.79M245.00K[{"date":"2019-12-31","value":32.89,"profit":true},{"date":"2020-12-31","value":49.13,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":29.71,"profit":true},{"date":"2023-12-31","value":1.26,"profit":true}]
Income After Taxes(72.66M)(65.36M)(90.04M)(60.20M)(7.87M)[{"date":"2019-12-31","value":-7265900000,"profit":false},{"date":"2020-12-31","value":-6536200000,"profit":false},{"date":"2021-12-31","value":-9003600000,"profit":false},{"date":"2022-12-31","value":-6020200000,"profit":false},{"date":"2023-12-31","value":-787000000,"profit":false}]
Income From Continuous Operations(66.25M)(55.78M)(70.54M)(54.41M)(7.87M)[{"date":"2019-12-31","value":-6624600000,"profit":false},{"date":"2020-12-31","value":-5578300000,"profit":false},{"date":"2021-12-31","value":-7053900000,"profit":false},{"date":"2022-12-31","value":-5441000000,"profit":false},{"date":"2023-12-31","value":-787000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(72.66M)(65.36M)(90.04M)(60.20M)(7.87M)[{"date":"2019-12-31","value":-7265900000,"profit":false},{"date":"2020-12-31","value":-6536200000,"profit":false},{"date":"2021-12-31","value":-9003600000,"profit":false},{"date":"2022-12-31","value":-6020200000,"profit":false},{"date":"2023-12-31","value":-787000000,"profit":false}]
EPS (Diluted)(2.43)(1.65)(1.49)(1.14)(0.36)[{"date":"2019-12-31","value":-243,"profit":false},{"date":"2020-12-31","value":-165,"profit":false},{"date":"2021-12-31","value":-149,"profit":false},{"date":"2022-12-31","value":-114,"profit":false},{"date":"2023-12-31","value":-36,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

AQST
Cash Ratio 5.14
Current Ratio 6.37
Quick Ratio 5.91

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AQST
ROA (LTM) -15.57%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AQST
Debt Ratio Lower is generally better. Negative is bad. 1.41
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.41

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AQST
Trailing PE NM
Forward PE NM
P/S (TTM) 5.91
P/B 0.00
Price/FCF NM
EV/R 5.33
EV/Ebitda NM

FAQs

What is Aquestive Therapeutics Inc share price today?

Aquestive Therapeutics Inc (AQST) share price today is $3.82

Can Indians buy Aquestive Therapeutics Inc shares?

Yes, Indians can buy shares of Aquestive Therapeutics Inc (AQST) on Vested. To buy Aquestive Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AQST stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Aquestive Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Aquestive Therapeutics Inc (AQST) via the Vested app. You can start investing in Aquestive Therapeutics Inc (AQST) with a minimum investment of $1.

How to invest in Aquestive Therapeutics Inc shares from India?

You can invest in shares of Aquestive Therapeutics Inc (AQST) via Vested in three simple steps:

  • Click on Sign Up or Invest in AQST stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Aquestive Therapeutics Inc shares
What is Aquestive Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Aquestive Therapeutics Inc (AQST) is $6.23. The 52-week low price of Aquestive Therapeutics Inc (AQST) is $1.84.

What is Aquestive Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Aquestive Therapeutics Inc (AQST) is

What is Aquestive Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Aquestive Therapeutics Inc (AQST) is 0.00

What is Aquestive Therapeutics Inc dividend yield?

The dividend yield of Aquestive Therapeutics Inc (AQST) is 0.00%

What is the Market Cap of Aquestive Therapeutics Inc?

The market capitalization of Aquestive Therapeutics Inc (AQST) is $348.30M

What is Aquestive Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Aquestive Therapeutics Inc is AQST

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top